Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPN217
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
HPN217 is a trispecific T cell activating construct (TriTAC) designed for the treatment of relapsed or refractory multiple myeloma. It incorporates three binding domains: one targeting B-cell maturation antigen (BCMA) on multiple myeloma cells, one targeting CD3 on T cells to facilitate T cell engagement and cytotoxicity, and one binding human serum albumin to extend the drug's half-life. By bringing T cells into close proximity with BCMA-expressing tumor cells, HPN217 promotes targeted immune-mediated killing of malignant plasma cells. The drug is being developed as an innovative immunotherapy for patients who have received multiple prior lines of therapy and has demonstrated promising efficacy and safety in early-phase clinical trials[1][2][3][6][8].
- Other names
- BCMA TriTAC
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on HPN217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPN217.